Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series.

× No keyword cloud information.

13 in total

1. Reproducibility and observer variability of transrectal ultrasound measurements of prostatic volume.

Authors: G N Collins; G M Raab; M Hehir; B King; W M Garraway
Journal: Ultrasound Med Biol Date: 1995 Impact factor: 2.998

2. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Authors: William T Cefalu; Lawrence A Leiter; Kun-Ho Yoon; Pablo Arias; Leo Niskanen; John Xie; Dainius A Balis; William Canovatchel; Gary Meininger
Journal: Lancet Date: 2013-07-12 Impact factor: 79.321

3. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.

Authors: Dandan Li; Tiansheng Wang; Su Shen; Zhenwei Fang; Yue Dong; Huilin Tang
Journal: Diabetes Obes Metab Date: 2016-12-19 Impact factor: 6.577

Review 4. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

Authors: Suzanne Geerlings; Vivian Fonseca; David Castro-Diaz; James List; Shamik Parikh
Journal: Diabetes Res Clin Pract Date: 2014-01-08 Impact factor: 5.602

5. Bladder dysfunction in type 2 diabetic patients.

Authors: Nur Kebapci; Aydin Yenilmez; Belgin Efe; Emre Entok; Canan Demirustu
Journal: Neurourol Urodyn Date: 2007 Impact factor: 2.696

6. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.

Authors: T Heise; E Seewaldt-Becker; S Macha; S Hantel; S Pinnetti; L Seman; H J Woerle
Journal: Diabetes Obes Metab Date: 2013-02-17 Impact factor: 6.577

7. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years.

Authors: Chung Cheng Wang; Michael B Chancellor; Jyh Ming Lin; Jui Hsiang Hsieh; Hong Jeng Yu
Journal: BJU Int Date: 2009-10-05 Impact factor: 5.588

Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series.

1. Reproducibility and observer variability of transrectal ultrasound measurements of prostatic volume.

2. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

3. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.

Review 4. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

5. Bladder dysfunction in type 2 diabetic patients.

6. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.

7. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years.

8. Impact of nocturia on health-related quality of life and medical outcomes study sleep score in men.

9. SGLT2 inhibitors: the latest "new kids on the block"!

10. Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats.

1. Lower Urinary Tract Symptoms Should Be Queried When Initiating Sodium Glucose Co-Transporter 2 Inhibitors.

Review 2. The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD.